Literature DB >> 3532121

"Replacement" of COOH-terminal truncation of v-fms with c-fms sequences markedly reduces transformation potential.

P J Browning, H F Bunn, A Cline, M Shuman, A W Nienhuis.   

Abstract

Protooncogenes when transduced by retroviruses may undergo structural modifications that render their gene products oncogenic. The c-fms gene encodes a transmembrane protein with tyrosine kinase activity that is very similar or identical to the receptor for the monocyte-macrophage colony-stimulating factor. Its transforming homologue (v-fms) in the Susan McDonough strain feline sarcoma virus causes fibrosarcomas in cats. Molecular cloning and sequence analysis of the cDNA that encodes the cytoplasmic domain of the human c-fms gene shows that the product of the transduced viral homologue, v-fms, is truncated at the COOH-terminal end. The COOH-terminal 40 amino acids of the c-fms gene product are replaced in the v-fms gene product by 11 amino acids encoded by the retroviral genome. Hybrid v-fms/c-fms genes, in which either the entire cytoplasmic domain or the COOH-terminal coding sequences of the v-fms gene were replaced by the corresponding segments of the c-fms gene, had a reduced ability to transform fibroblasts despite a high level of encoded protein on the cell surface. These data indicate that the COOH-terminal modifications contribute to the transforming potential of the v-fms viral oncogene product.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3532121      PMCID: PMC386809          DOI: 10.1073/pnas.83.20.7800

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin.

Authors:  C Shih; B Z Shilo; M P Goldfarb; A Dannenberg; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

2.  Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor.

Authors:  M Wigler; A Pellicer; S Silverstein; R Axel
Journal:  Cell       Date:  1978-07       Impact factor: 41.582

3.  DNA sequence analysis by primed synthesis.

Authors:  A J Smith
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

4.  Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy.

Authors:  R J Tushinski; I T Oliver; L J Guilbert; P W Tynan; J R Warner; E R Stanley
Journal:  Cell       Date:  1982-01       Impact factor: 41.582

5.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

6.  Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro.

Authors:  S I Shin; V H Freedman; R Risser; R Pollack
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

7.  Transformation by the v-fms oncogene product: role of glycosylational processing and cell surface expression.

Authors:  E J Nichols; R Manger; S Hakomori; A Herscovics; L R Rohrschneider
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

8.  McDonough feline sarcoma virus: characterization of the molecularly cloned provirus and its feline oncogene (v-fms).

Authors:  L Donner; L A Fedele; C F Garon; S J Anderson; C J Sherr
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Gene products of McDonough feline sarcoma virus have an in vitro-associated protein kinase that phosphorylates tyrosine residues: lack of detection of this enzymatic activity in vivo.

Authors:  M Barbacid; A V Lauver
Journal:  J Virol       Date:  1981-12       Impact factor: 5.103

View more
  9 in total

1.  Analysis of functional domains of the v-fms-encoded protein of Susan McDonough strain feline sarcoma virus by linker insertion mutagenesis.

Authors:  S D Lyman; L R Rohrschneider
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

2.  Tyrosine phosphorylations in vivo associated with v-fms transformation.

Authors:  D K Morrison; P J Browning; M F White; T M Roberts
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

3.  Evolution, expression, and chromosomal location of a novel receptor tyrosine kinase gene, eph.

Authors:  Y Maru; H Hirai; M C Yoshida; F Takaku
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

4.  FMS mutations in myelodysplastic, leukemic, and normal subjects.

Authors:  S A Ridge; M Worwood; D Oscier; A Jacobs; R A Padua
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

5.  CSF-1R up-regulation is associated with response to pharmacotherapy targeting tyrosine kinase activity in AML cell lines.

Authors:  Michael Kogan; Tracy Fischer-Smith; Rafal Kaminsky; Gabrielle Lehmicke; Jay Rappaport
Journal:  Anticancer Res       Date:  2012-03       Impact factor: 2.480

6.  Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1.

Authors:  B M Kacinski; D Carter; K Mittal; L D Yee; K A Scata; L Donofrio; S K Chambers; K I Wang; T Yang-Feng; L R Rohrschneider
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

7.  Expression of a fms-related oncogene in carcinogen-induced neoplastic epithelial cells.

Authors:  C Walker; P Nettesheim; J C Barrett; T M Gilmer
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Differential effects of carboxy-terminal sequence deletions on platelet-derived growth factor receptor signaling activities and interactions with cellular substrates.

Authors:  K Seedorf; B Millauer; G Kostka; J Schlessinger; A Ullrich
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

9.  Random mutagenesis of CSF-1 receptor (FMS) reveals multiple sites for activating mutations within the extracellular domain.

Authors:  T van Daalen Wetters; S A Hawkins; M F Roussel; C J Sherr
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.